6533b7defe1ef96bd1275919

RESEARCH PRODUCT

CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome.

Giampiero La RoccaRita AnzaloneSimona CorraoFrancesca MagnoFrancesca RappaSalvatore Marasa'Concetta SergiGiovanni ZummoFrancesco CappelloCzarnecka AmMarasà L

subject

AdultCD4-Positive T-LymphocytesCarcinoma Ductal BreastDown-RegulationBreast NeoplasmsDendritic CellsCD8-Positive T-LymphocytesMiddle AgedCD1APrognosisImmunohistochemistryAntigens CD1Gene Expression Regulation NeoplasticReceptors EstrogenPredictive Value of TestsLymphatic MetastasisHumansFemaleReceptors ProgesteroneAged

description

AIMS: CD1a is a molecule belonging to the highly conserved group of CD1 proteins. Its expression in dendritic cells is related to the presentation of tumour-derived glycolipid antigens to T cells and, consequently, the development of a successful antitumour response. The aim was to investigate the presence of CD1a+ cells in both primary tumours and lymph nodes (LN) of a series of 35 invasive ductal carcinomas by both immunohistochemistry and reverse transcription-polymerase chain reaction. METHODS AND RESULTS: CD1a antigen was more expressed in N0 than N1 breast cancer (P < 0.0001) in both primary lesions and LN metastases and correlated positively and significantly with oestrogen (ER) (P = 0.0025) and progesterone (P = 0.0226) receptor (PR) status, as well as CD4+ and CD8+ T-lymphocyte infiltration. CONCLUSIONS: This is the first report to show a link between CD1a+ mononuclear cells in breast cancer and in paired LN metastases. The positive and significant correlations between the number of CD1a+ cells and positivity of the primary tumour for ER and PR suggest a possible role for CD1a as a prognostic marker for breast cancer, raising the possibility that hormone receptor-positive breast cancer patients may have a better prognosis in the presence of greater dendritic cell infiltration.

10.1111/j.1365-2559.2007.02919http://hdl.handle.net/10447/7154